Skip to main content

Most Popular Diabetes News

Orforglipron, Eli Lilly's once-daily oral GLP-1 receptor agonist, is being studied in ongoing clinical trials for obesity and type 2 diabetes. Data shows A1C reductions...
The FINE-ONE trial by Bayer investigates Kerendia's effectiveness in preventing kidney disease progression in people with type 1 diabetes. This pivotal trial could...
Novo Nordisk is set to discontinue Levemir, a key long-acting insulin, by the end of 2024 due to manufacturing priorities and better alternatives, impacting supply and...
A new study reveals only 40% of people with diabetes undergo vital kidney screenings. Learn about the importance of eGFR and uACR tests for preventing CKD, and the...
The T1DEXI study sheds light on the impact of exercise on type 1 diabetes, including how to manage hypoglycemia and hyperglycemia. In addition, here are some practical...
Explore the VITAL-CGM trial, which investigates if using a combination of CGM and WeightWatchers can lower A1C in people with type 2 diabetes.
Descubre las razones por las cuales los hispanos tienen un riesgo elevado de sufrir diabetes tipo 2 y encuentra consejos de expertos para prevención y manejo de la...
Omnipod 5 users will soon be able to control their AID system through a free iPhone app available in the new year. Like the Android app, iPhone users will be able to...
Explore the benefits of Nevro's HFX spinal cord stimulation device for diabetic peripheral neuropathy. Recent studies show up to two years of pain relief and enhanced...
In case you missed them, here are our top stories from October 2023 that cover upcoming therapies, groundbreaking research, and more.
Join a study investigating BMF-219, a menin inhibitor that could stimulate healthy beta cell regeneration and potentially slow diabetes progression.
People with diabetes who are U.S. citizens or permanent residents can apply for a free lifetime America the Beautiful Pass, which offers access to over 2,000 parks,...
Medtronic unveils Simplera, the latest CGM approved in Europe for people with diabetes ages two and older. A sleek, disposable device, Simplera rivals the Dexcom G7 and...
Lilly’s SURMOUNT-4 trial shows that Mounjaro (tirzepatide) offers remarkable weight loss in patients with a BMI of over 30. Full SURMOUNT-3 trial results highlighted the...
Researchers find automated insulin delivery (AID) systems, the MiniMed 780G and Omnipod 5, showed significant improvement in time in range for everyday users. This real-...
Ongoing hostilities and violence across the world leave people with diabetes in crisis and without access to essential resources. What can be done to help?
Explore the profound issue of diabetes stigma and steps we can take to combat it. From the Language Matters movement to personal stories and global pledges, discover how...
This trial is investigating a new oral medication, INV-202, which is designed to improve regulation in the kidney, liver, and pancreas.
Determining ideal carbohydrate intake for those with type 1 diabetes remains complex. Two studies at EASD 2023 highlight the benefits of a plant-based diet and...
Data presented at EASD 2023 reveals orforglipron's potential in type 2 diabetes management. The new oral GLP-1 medication demonstrated significant reductions for A1C and...

Pages